



Press Release

MediVision Medical Imaging Ltd.

☎ +(972) 4-989-4884

☎ +(972) 4-989-4883

✉ YTM industrial area POB 7 Yokneam Elit, Israel 20692

✉ noam@medivision-ois.com

FOR IMMEDIATE RELEASE

MediVision Presents Management's Report for of the year ended at December 31, 2010

Haifa, Israel, MediVision Medical Imaging Ltd. ("MediVision", "MV", EURO.NM: MEDV) released today (Thursday, April 28th, 2011) information concerning its operations and financial results for the period ended December 31th, 2010.

CONSOLIDATED STATEMENT OF OPERATIONS FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2010: (in thousands U.S. Dollars, except per-share data)

		2010	2009 **
	Notes	\$000	Restated *
Sales	9.1	-	6,377
Cost of sales	9.2	-	(3,402)
Gross profit		2,975	
Other income	9.3	1,006	2,147
Selling and marketing expenses	9.4	-	(2,195)
General and administrative expenses	9.5	(166)	(1,670)
Research and development costs, net	9.6	-	(1,290)
Operating loss		840	(33)
Financial income			60
Financial expenses		(246)	(592)
share of loss of an associate		(809)	(2,168)
loss before tax		(215)	(2,733)
Income tax expenses	10	-	(2)
Loss for the year		(215)	(2,735)
Other comprehensive income			
Exchange differences on translating foreign operations		-	20
Total comprehensive loss		(215)	(2,715)
attributable to:			
Owners of the parent		(215)	(2,417)
Non-controlling interests		-	(298)
		(215)	(2,715)
Loss per share			
Basic, loss for the year attributable to ordinary equity holders of the Parent		\$ (0.02)	\$(0.33)

Management's Discussion and Analysis of the Financial Condition and Results of Operations of the Company

General and Administrative Expenses - General and Administrative expenses include mainly professional services, and various provisions. Total General and Administrative expenses for the twelve months ended December 31, 2010 were \$163,000, consisted mainly of professional services.

Other Income Net - This income reflects the profit from decreasing MediVision share in OIS as a result of investment of third party in OIS and realization of OIS shares in the total amount of \$857,000 (for further details see note 3 of the financial statement) and profit from an agreement with a supplier to reduce the company's debt to that supplier by the amount of \$166,000.

CONSOLIDATED BALANCE SHEET AS OF DECEMBER 31, 2010:
(in thousands U.S. Dollars, except per-share data)

		2010	2009
			Restated *
	Notes	\$000	\$000
Assets			
Current assets			
Cash and cash equivalents		-	27
Trade and other receivables	3	65	175
		65	202
Non-current assets			
Investment in an associate	4	1,838	2,046
Total assets		1,903	2,248
Liabilities and equity			
Current liabilities			
Credit from banks and shareholders	5	1,892	1,168
Trade and other payables	6	178	1,036
		2,070	2,204
Non-current liabilities			
Employee benefit liability		65	61
Total liabilities		2,135	2,265
Equity			
Issued capital	8	215	215
Share premium		9,302	9,302
Capital reserve		(311)	(311)
Retained deficit		(9,439)	(9,223)
Total equity		(232)	(17)
Total equity and liabilities		1,903	2,248

Investments in an associate - During the year end financial closing process OIS discovered errors in the treatment of warrants to purchase shares of OIS common stock and embedded conversion options issued in connection with convertible notes. As a result the management of OIS decided to restate OIS financial statements for 2007, 2008, all quarters of 2009 and 3 first quarters of 2010. Details about the restatement are available in OIS 10K which is available at OIS website:

http://www.oisi.com/index.php?option=com_content&view=section&layout=blog&id=12&Itemid=73

MediVision management decided to restate the Financial reports of 2009 and to reflect the influence of the restatement accordingly.

Long-term debt - reflects convertible loans from shareholders. According to the agreement with these shareholders they have the right to convert the loans at any time. Until the day of publishing the financial reports the company received request from several such shareholders to convert the loans. The conversion as of March 31, 2011 will reduce the loans and the company will issue 5,703,270 additional shares.

Total Equity - During the Quarter ended December 31st, 2010, total equity was decreased by \$215,000 reaching \$232,000. This is mainly a result of losses in OIS during the period (please see note 4 to the financial statements).

Events following the reporting period

On 22 March 2011 the board of Directors decided to recommend to the General Assembly of the Shareholders on **voluntary dissolution** of the company, Due to the fact that the company has no more business activity other than holding OIS shares. The intention of the company is to distribute the balance of OIS shares to the shareholders after paying all of the obligations by realizing part of OIS shares as described above.

In addition, after the reporting period the company has realized OIS shares in consideration of \$329,000. Following the realization, the company's holdings in OIS shares and voting rights decreased to 28.48%. The capital gain derived from the realization of shares was \$237,000.

The Board of Directors approved on 22 March 2011 an agreement to sell additional shares of OIS on May 2011 in the amount of \$143,000 in order to meet the company cash flow requirements.

Concerning the fact that repayment of the shareholders loans will require to sell a large amount of shares the board of directors recommended on November 15, 2010 to request from the shareholders to convert the loans. Until the day of publishing the financial statements the company received such a request from two shareholders.

This Release contains certain forward-looking statements and information relating to the Company that are based on the beliefs of the Management of the Company as well as assumptions made by and information currently available to the Management of the Company. Such statements reflect the current views of the Company with respect to future events, the outcome of which is subject to certain risks including but not limited to as listed below and other factors, which may be outside of the Company's control. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results of outcomes may vary materially from those described herein as projected, anticipated, believed, estimated, expected or intended. Such abovementioned risks include but are not limited to:

1. Uncertain market acceptance of Company products - The Company's future growth and profitability will depend, in large part, on the acceptance by the market of the Company's existing and proposed products. This acceptance will be substantially dependent on educating the market as to full capabilities, distinctive characteristics, perceived benefits and efficacy of the Company's existing and proposed products. In addition, the future success of the Company's products will depend on their acceptance by customers and on such customers' willingness and ability to purchase such products. There can be no assurance that the Company's products will receive the necessary market acceptance. Failure of the Company's existing and/or proposed products to gain market acceptance could have a material adverse effect on the Company's business, financial condition and results of operations.
 2. New products - The Company, through its Research and Development teams, engages in the development of new technologies and products and in the upgrading and improvement of existing ones. There is no certainty that development of these technologies and/or products will be completed, successfully, or at all, or if completed successfully, that a market for them will exist.
-

For more information, please contact: **Noam Allon**
President, Chief Executive Officer
Tel. +972-4-9894884; Fax +972-4-9894883
E-mail: noam@medivision-ois.com